NVUS Novus Therapeutics Inc.

0.8
+0.02  (+3%)
Previous Close 0.78
Open 0.75
Price To Book 0.64
Market Cap 10,379,938
Shares 12,974,923
Volume 10,529
Short Ratio
Av. Daily Volume 67,618

NewsSee all news

  1. Novus Therapeutics to Participate in Two Upcoming Investor Conferences

    Novus Therapeutics, Inc. (NASDAQ:NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial discontinued July 2016 due to poor data
Galeterone - ARMOR3-SV
Cancer - castration-resistant prostate cancer (CRPC)
Announced in August 2016 that Phase 2 trial enrollment has been discontinued.
Galeterone - ARMOR2
Xtandi (enzalutamide) refractory metastatic castration-resistant prostate cancer (mCRPC)
Phase 1 data presented June 11, 2019, 1pm.
OP0201- C-002
Healthy volunteers
Phase 1 data released April 22, 2019. Safety and tolearbility objectives met.
OP0201 C-001
Healthy volunteers
Phase 1 data released April 22, 2019. Safety and tolerability objectives met.
OP0201
Acute Otitis Media - adults
Phase 2a data due 1H 2020.
OP0201 - C-006
Acute Otitis Media - children
Phase 1 data released April 22, 2019. Safety and tolerability objectives met.
OP0201 - C-001
Healthy volunteers

Latest News

  1. Novus Therapeutics to Participate in Two Upcoming Investor Conferences

    Novus Therapeutics, Inc. (NASDAQ:NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate